The 8th Liver Roundtable by the Asian Liver Radiation Therapy (ALRT) Special Interest Group
The 8th Liver Roundtable, organized by the Asian Liver Radiation Therapy (ALRT) Special Interest Group, took place on April 12, 2025, at Zhongshan Hospital, affiliated with Fudan University in Shanghai, China. The event convened prominent specialists in liver cancer treatment from across Asia to present clinical research findings, share institutional experiences, and foster collaboration in the field of liver stereotactic body radiotherapy (SBRT).
The scientific sessions began with a talk by Jinsil Seong (Korea) on the efficacy of stereotactic ablative radiotherapy (SABR) for oligometastatic hepatocellular carcinoma (HCC).
This was followed by a presentation by Sang Min Yoon (Korea) comparing SBRT with hepatic resection for treatment-naive BCLC stage 0 HCC.
Shi-Suo Du (China) presented findings from a Phase II clinical study on SBRT with continued first-line therapy as a resistance-overcoming modality in oligoprogressive HCC.
Yue Jin Bo (China) discussed a Phase III study on delaying second-line therapy through radiotherapy in oligoprogressive HCC.
Shih-Kai Hong (Taiwan) then provided an update on the TASABR trial.
The morning concluded with a session on SCART (Stereotactic Central Ablative RT) application in liver cancer treatment by Jun Yang (China).
The afternoon resumed with Zhang Xiang (China) presenting a Phase II clinical trial involving Bevacizumab and Epalutovorimab combined with SBRT for BCLC Stage C HCC with portal vein tumor thrombus or extrahepatic oligometastases.
The session on institutional experiences and challenges with liver SBRT included insights from Chiang Mai University Hospital (Thailand), and Siriraj Hospital (Thailand), where each institution shared their respective approaches and implementation barriers.
Finally, the Zhongshan Hospital team presented a session on the Liver SBRT Consensus, followed by general discussion on future collaboration plans and practical issues, led by Jinsil Seong.
Throughout the event, participants exchanged valuable clinical experiences, trial data, and insights into advanced treatment strategies.
We brought the knowledge gained from this roundtable back to our hospital and are committed to applying it to the fullest extent of our hospital’s capabilities to enhance liver cancer treatment.
